Amit Goyal, MD

Amit Goyal, MD

Amit Goyal, MD

Amit Goyal (@AmitGoyalMD) is an interventional cardiology fellow at the Cleveland Clinic. He completed his medical school at the University of California, San Diego and went on to enjoy residency training in the Osler Program at Johns Hopkins, where he served as the Assistant Chief of Service of the Barker Firm. As ACS he founded Osler Grand Rounds, an interactive mystery case discussion, and helped establish a novel morning report structure integrating bedside skills education. He is looking forward to a career in interventional cardiology and medical education. He relishes time with friends and family including with his wife Riddhi and sons Dhruv, Aarav, and Atharv.

Articles by Amit Goyal, MD

Amit Goyal, MDCardiology | April 17, 2025
Dr. Amit Goyal of the CardioNerds analyzed the BHF PROTECT-TAVI trial.
Read More
Amit Goyal, MDCardioNerds | April 17, 2025
The REPAIR study offers the most comprehensive real-world assessment of outcomes after mitral TEER.
Amit Goyal, MDCardiology | April 17, 2025
The ROLLER COASTR-EPIC22 trial is the first randomized head-to-head comparison of three plaque modification techniques.
Amit Goyal, MDCardiology | April 17, 2025
The observational REDUCER-I study aims to evaluate the real-world safety and effectiveness of the coronary sinus reducer.
Amit Goyal, MDCardioNerds | April 17, 2025
Dr. Amit Goyal details a study which explored the role of coronary sinus reducer in Coronary microvascular dysfunction.
Amit Goyal, MDCardiology | April 17, 2025
The possibility of DCBs to rescue side branches during provisional coronary bifurcation stenting is appealing.
Amit Goyal, MDCardioNerds | April 17, 2025
Dr. Amit Goyal details the first-in-human study of the Magenta Elevate system.
Amit Goyal, MDAHA 2024: CardioNerds | April 17, 2025
A study highlights the significant HCRU and costs associated with ATTR-CM.
Amit Goyal, MDAHA 2024: CardioNerds | April 17, 2025
Promising long-term outcomes from the ongoing OLE of the ATTRibute-CM trial highlight the efficacy of acoramidis.
Amit Goyal, MDTCT 2024 | April 17, 2025
Results of the EARLY TAVR trial introduced a potential paradigm shift in managing asymptomatic high-gradient severe AS.
Amit Goyal, MDTCT 2024 | April 17, 2025
Two pivotal trials—EARLY TAVR and EVOLVED—were presented, each exploring early intervention in asymptomatic severe AS.
Amit Goyal, MDTCT 2024 | April 17, 2025
ECLIPSE investigated whether OA provides better outcomes than conventional balloon angioplasty in calcified coronary lesions.
Amit Goyal, MDTCT 2024 | April 17, 2025
An analysis of PROTECTED TAVR trial highlighted potential regional differences in the efficacy of CEP during TAVR.
Amit Goyal, MDCardioNerds | April 17, 2025
The MATTERHORN trial demonstrates that, for patients with HF and FMR, M-TEER is non-inferior to surgical mitral valve repair.
Amit Goyal, MDCardioNerds | April 17, 2025
The RESHAPE-HF2 trial offers further insights into the transcatheter management of patients with HFrEF and FMR.
Amit Goyal, MDCardiology | April 17, 2025
The SENIOR-RITA trial investigates the optimal management strategy for older adults with NSTEMI.
Amit Goyal, MDAtrial Fibrillation | April 17, 2025
The EPIC-CAD trial addresses a crucial question in managing patients with both atrial fibrillation and stable CAD.
Amit Goyal, MDESC Congress 2024 | April 17, 2025
The SCOFF trial challenges the long-standing practice of fasting before cardiac catheterization procedures.
Amit Goyal, MDESC Congress 2024 | April 17, 2025
The NOTION 3 trial contributes important data to the ongoing debate about the role of PCI before TAVI in patients with CAD.
Amit Goyal, MDCardiology | April 17, 2025
While transvenous pacemakers have been the standard, the emergence of leadless pacemakers offers a promising alternative,